Document Detail


The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide.
MedLine Citation:
PMID:  10806137     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We studied the effect of abrupt discontinuation of inhaled nitric oxide (iNO) in patients receiving this drug for treatment of acute hypoxemic respiratory failure (AHRF), in order to determine the need for continued therapy, the incidence and nature of adverse events, and the risk factors predicting these adverse events. Thirty-one patients who showed an initial increase in Pa(O(2)) of > 20 mm Hg in response to iNO underwent a discontinuation trial at 10 to 30 h after beginning iNO. Indwelling arterial and pulmonary artery catheters facilitated monitoring of hemodynamic and gas-exchange parameters. For the group, discontinuation of iNO caused a significant decrease in Pa(O2 ), arterial and mixed venous oxygen saturation, and ratio of Pa(O(2)) to fraction of inspired oxygen (FI(O(2))). Three patterns of response were observed. Eight of 31 (25.8%) patients had minimal changes in oxygenation or hemodynamics, suggesting no need for ongoing therapy. Fifteen of 31 (48%) patients had worsened gas exchange as a predominant response. Eight of 31 patients exhibited hemodynamic collapse, defined as > 20% fall in cardiac output and/or mean arterial blood pressure. In this last subgroup, the pattern of cardiovascular changes suggested that this response arose from an acute increase in right ventricular afterload, and was not a consequence of gas-exchange abnormalities. In all cases, reinstitution of iNO promptly reversed worsened hemodynamics and gas exchange. Independent factors associated with an increased risk of cardiovascular collapse included multisystem organ failure, older age, and initial blood pressure increase in response to iNO; a smaller change in the ratio of Pa(O(2)) to FI(O(2)) with initiation of iNO therapy also tended to correlate with this phenomenon. We conclude that careful and monitored discontinuation of iNO in patients with AHRF will identify substantial fractions of patients who are either receiving no benefit from this therapy or who require iNO to maintain an adequate circulation and are therefore at risk for adverse outcome with transport or inadvertent discontinuation of iNO. Future trials of iNO should recognize this complication of such therapy and include assessments for it.
Authors:
J Christenson; A Lavoie; M O'Connor; S Bhorade; A Pohlman; J B Hall
Related Documents :
11057797 - Inhaled nitric oxide does not enhance lipid peroxidation in patients with acute respira...
52767 - Positive end-expiratory pressure in weaning patients from controlled ventilation. a pro...
2930107 - Systemic gas embolism complicating mechanical ventilation in the adult respiratory dist...
22448327 - Pulmonary bacterial communities in surgically resected noncystic fibrosis bronchiectasi...
9272297 - Clinical, laboratory and immunogenetic aspects of arthritis associated with chronic lym...
22615327 - Gait variability measures reveal differences between multiple sclerosis patients and he...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  American journal of respiratory and critical care medicine     Volume:  161     ISSN:  1073-449X     ISO Abbreviation:  Am. J. Respir. Crit. Care Med.     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-06-21     Completed Date:  2000-06-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9421642     Medline TA:  Am J Respir Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1443-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, The Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Administration, Inhalation
Anoxia / complications
Female
Hemodynamics*
Humans
Male
Middle Aged
Nitric Oxide / administration & dosage*
Pulmonary Gas Exchange*
Respiration, Artificial
Respiratory Insufficiency / complications,  physiopathology*,  therapy*
Shock / etiology
Chemical
Reg. No./Substance:
10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiv...
Next Document:  How is mechanical ventilation employed in the intensive care unit? An international utilization revi...